Nuvectis Pharma, Inc. (NVCT) Stock

Nuvectis Pharma, Inc. (NVCT) is a Healthcare stock trading at $13.94 (as of 2026-06-18), with a market capitalization of $258.62M and a trailing P/E of -7.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Valuation — source: SEC EDGAR (first-party)
Price	$13.94
Market Cap	$258.62M
P/E Ratio	-7.4
Price / Book	18.19
DCF Value (model)	$-9.09
DCF Upside vs Price	-165.2%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-191.0%
Current Ratio	2.27

Valuation vs Sector & Industry
Stock P/E	-7.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-135.6%
vs Industry	-143.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($6.38M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ron Bentsur
Employees	13
Country	US
IPO Date	2022-02-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.